Therapeutic vulnerabilities and pan-cancer landscape of BRAF class III mutations in epithelial solid tumors
{{output}}
Background: Kinase-impaired class III BRAF mutations have recently received attention as a possible prognostic factor and therapeutic target. Class III BRAF variants differ from class I and class II mutations in terms of mechanis... ...
